Treatment of Actinic Keratoses (AK) on the Face

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Actinic Keratoses
Interventions
DRUG

ingenol mebutate 0.015%

one cycle of ingenol mebutate 0.015% on two 25 cm2 treatment areas

OTHER

dermasil lotion

Dermasil lotion has 1% dimethicone as its active ingredient - part of the family of silicone oils, is a hypoallergenic, noncomedogenic, and nonacnegenic agent

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

LEO Pharma

INDUSTRY

lead

Icahn School of Medicine at Mount Sinai

OTHER